Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SAR439459
- Development stage
- Phase 1
- Lead developer
- Sanofi
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
SAR439459 is a human anti-transforming growth factor beta (TGFβ) monoclonal antibody that neutralizes all isoforms of TGFβ (TGFβ1, TGFβ2, and TGFβ3). It was developed by Sanofi for the treatment of advanced solid tumors and osteogenesis imperfecta. By inhibiting TGFβ signaling, it aims to relieve immunosuppression in the tumor microenvironment and enhance the efficacy of immune checkpoint inhibitors.
- Other names
- GC-2008GC2008GC 2008
02
Targets
TGFB1 (Transforming growth factor Beta-1 proprotein)TGFB2 (Transforming growth factor beta 2)TGFB3 (Transforming growth factor beta 3)
Beyond the preview
Go deeper on SAR439459.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SAR439459.